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Purpose: To investigate the long-term outcome of esophageal squamous cell carcinoma (SCC) treated by
irradiation with or without concurrent chemotherapy.
Methods and materials: A prospective clinical trial was carried out from 1998 to 2000. One hundred and eleven
patients were randomly enrolled to receive either late course accelerated hyperfractionated irradiation (LCAF) or
LCAF with concurrent chemotherapy (LCAF + CT). For LCAF, 41.4 Gy in 23 fractions was first delivered at five
fractions per week, followed by 27 Gy in 18 fractions at two 1.5 Gy fractions a day. Concurrent chemotherapy of
cis-platinum and 5-fluorouracil was administered for four cycles. Overall survival (OS), locoregional recurrence and
distant metastasis were observed. Late toxicity was scored by RTOG criteria, and quality of life (QOL) was also
evaluated.
Results: The median follow-up time was 24 months for all patients and 138 months for 17 living patients. Median
survival time was 25 months and 32 months in LCAF and LCAF + CT (p= 0.653), respectively. For an entire group of
patients, overall survivals were 34%, 27% and 22%; locoregional recurrence rates were 30%, 36% and 41%; and
distant metastasis rates were 26%, 28% and 29% at 5-yr, 8-yr and 10-yr, respectively. Incidences of ≥ Grade 3 late
toxicity were 29% at 10-yr. There were no statistically significant differences between LCAF and LCAF + CT with
respect to the parameters mentioned above. Cumulative incidence of late toxicities of ≥ Grade 3 increased sharply
after the attained age of 70 years. Eighty-eight percent of patients lived with good KPS (≥ 90) and 94% could eat
regular or soft diet.
Conclusion: The long-term outcome of esophageal SCC patients who received LCAF or LCAF + CT was good. The
locoregional and distant failures occurred more often in the first three years after treatment, but could continuously
occur up to 10 years. The late toxicity was acceptable. Late toxicities ≥ Grade 3 were more likely to occur in elderly
patients. QOL was good in living patients.
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Esophageal carcinoma is one of the most common can-
cers in the world with an estimated 482,300 new cases
and 406,800 yearly deaths worldwide [1]. Currently,
concurrent chemoradiation is the standard of care for
esophageal carcinoma. However, outcome is still unsat-
isfactory due to poor local control. To improve local
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reproduction in any medium, provided the oresophageal carcinoma has been investigated since the
1990s. In our center, we started the clinical trials on
late course accelerated hyperfractionated irradiation
(LCAF) in 1988 [2]. We hypothesized that tumors
began accelerated proliferation around 4 weeks after
the commencement of irradiation. Thus, we used accel-
erated irradiation about 4.6 weeks after conventional
fractionation irradiation in the hopes that LCAF could
effectively inhibit the accelerated proliferation of surviv-
ing tumor cells. In the 2000s, we reported a 5-year
overall survival rate of around 30% [3-6]. In order to
further improve the treatment efficacy, we combinedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in a prospective randomized clinical trial, which
demonstrated a trend towards better survival compared
to LCAF alone [3]. In the current article, we presented
the long-term outcome of this trial after a 10 year fol-
low-up, which includes survival, failure patterns, late
toxicity and quality of life (QOL).
Methods and materials
Study design
From March 1998 to July 2000, 111 patients were
recruited into a prospective randomized clinical trial. The
patient eligibility criteria were as follows: (1) Esophageal
squamous cell carcinoma (SCC) confirmed by histology or
cytology; (2) Clinical stages of T1-4N0-1M0 (UICC, 1997);
(3) Baseline of laboratory tests met chemoradiation
requirements, including a white blood cell count of
> 4.0*109/L, platelet count of > 100 *109/L, adequate renal
function (serum creatinine concentration of < 1.5 mg/dL,
blood urea nitrogen of < 8 mmol/L and creatinine clear-
ance of > 65 mL per minute), and normal liver function;
(4) Karnofsky performance status (KPS) ≥ 70; (5) No prior
therapy; (6) No previous malignancies; and (7) No serious
comorbidity that would preclude safe administration of
treatment. Exclusion criteria included the followings:
(1) Evidence of esophageal perforation or deep ulceration;
(2) Complete obstruction of the esophageal lumen;
(3) Esophageal bleeding; (4) Involvement of supraclavicular
lymph nodes; and (5) Distant metastases. Pretreatment eva-
luations for staging included chest computed tomography
(CT), esophageal barium photography and ultrasound
examinations of liver, kidney, spleen and retroperitoneal
lymph nodes.
Patients were randomized into two arms, LCAF + CT
or LCAF alone. Informed consent was obtained from
each patient on the day of admission. The study protocol
conforms the guidelines of the World Medical Associ-
ation. Declaration of Helsinki. The ethic’s Committee of
our approved the protocol and all patients gave their
informed consent for the inclusion in the study.
Treatment arms
LCAF
This consisted of two phases. In the first phase, 41.4 Gy
in 23 fractions was delivered by conventional fraction-
ation of 1.8 Gy per fraction, one fraction per day and five
fractions per week. In the second phase, 27 Gy in 18
fractions was given by two 1.5 Gy fractions per day, each
with an interval of > 6 h. A total of 68.4 Gy was irra-
diated in 41 fractions for 6.4 weeks.
Irradiation was carried out with a 6-MV photon and a
two anterior oblique field technique associated with a
pair of appropriate wedges for cervical esophageal
lesions or a three-field approach with one anterior and apair of posterior oblique fields for lesions in the thorax.
Irradiation portals covered the primary tumor and meta-
static nodes, which were shown on CT and a barium
photographs. Margins of 2–3 cm were added for sub-
clinical invasion and set-up error. At the long axis, mar-
gins of 3 cm proximally and 5 cm distally were set to
sufficiently encompass the submucosal invasion. The
dose was prescribed to the isocenter without inhomo-
geneity correction. In the second phase of irradiation,
the irradiation fields were reduced to 2-cm margins be-
yond the superior and inferior ends of the esophageal le-
sion. No prophylactic irradiation was given in the
supraclavicular regions.
Chemotherapy
In the LCAF + CT arm, patients received concurrent
chemotherapy once a month for four cycles of PF regi-
men (cis-platinum of 25 mg/m2 daily and 5-Fluorouracil
of 600 mg/m2 daily for three consecutive days) during
and after irradiation.
Follow-up
Follow-up was performed on patients every four months
for the first year, every six months for two years, annu-
ally for two years, and every other year, thereafter. Each
follow-up visit included complete history, physical exam-
ination, evaluations of quality of life, a blood test, a chest
X-ray film, esophageal barium radiography and a chest
CT. Late treatment-related toxicity was scored by RTOG
criteria.
Definition of locoregional recurrence
Locoregional recurrence was defined as esophageal and/
or regional lymph node failures. Once esophageal recur-
rence was suspected, a biopsy was required. When node
recurrence was suspected, CT, MRI, or PET/CT should
be performed. Lymph node recurrence was determined
by one of the following criteria: (1). Nodes reappeared
after complete disappearance; (2). Nodes were enlarged
after remaining stable; and (3). New nodes of > 1 cm in
diameter appeared in the mediastinal or abdominal
regions where no enlarged nodes existed prior to
irradiation.
Distant node metastasis
Distant node metastasis included M1a and M1b (UICC,
2002). M1a was referred to as supraclavicular or cervical
lymph node metastases from the upper thoracic esopha-
geal SCC or celiac axis nodes from the distal esophageal.
M1b included all other patterns of distant nodal spread.
QOL assessment
QOL was evaluated by the following criteria: (1) The
diet that patient can swallow, which was categorized
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food; (2) Cough, which was graded according to com-
mon terminology criteria for adverse events (CTCAE,
version 4.0); (3) Hemoptysis by CTCAE (version 4); and
(4) General conditions by KPS score.
Statistical analysis
Overall survival rate (OS), locoregional recurrence rate,
and distant metastasis rate were the main endpoints
estimated by the Kaplan-Meier model (KM) (SPSS, ver-
sion 16.0) and the significance of difference was evalu-
ated by the log-rank test. The incidence of severe late
toxicity, which was defined as those of Grade ≥ 3, was
also estimated by KM model. Attained age was used,
which was defined as the age when events occurred
(Attained Age = Age at diagnosis + Time to the event).
The observation started from the first day of treatment
until death or the last follow-up visit.
Results
Survival
From March 1998 to July 2000, 111 patients were ran-
domly enrolled in LCAF (57) and in LCAF + CT (54).
The clinical characteristics were well balanced between
the two arms (Table 1). Ninety-four patients died by the
last follow-up visit in December 2010 and 17 patients
survived with 9 patients in LCAF and 8 patients inTable 1 Patient clinical characteristics
LCAF LCAF + CT P value
No. of patients 57 54
Gender, n (%)
Male 36 (63) 42 (78) 0.092
Female 21 (39) 12 (22)
Age (yr)
Median (range) 61.0 (41–74) 54.5 (39–74) 0.433
KPS, n (%)
70 3 (5) 2 (4) 0.692
80-100 54 (95) 52 (96)
Lesion location, n (%)
Cervical 3 (5) 4 (7) 0.724
Upper thorax 18 (32) 12 (22)
Middle thorax 34 (60) 36 (67)
Lower thorax 2 (3) 2 (4)
Esophageal length at long axis
Median (range) (cm) 6.0 (1–10) 6.0 (2–9) 0.132
Stage, n (%)
T1-2N0M0 11 (19) 11 (20) 0.690
T3-4N0M0 37 (65) 37 (69)
T1-4N1M0 9 (16) 6 (11)LCAF + CT. The median follow-up time was 24 months
(1 month to 128 months) for entire group and
138 months (126 months to 152 months) for those alive.
Median survival times were 25 months (CI, 21.3-28.7)
and 32 months (CI, 8.6-55.4) for LCAF and LCAF + CT,
respectively. OS at 5-year, 8-year and 10-year were 34%,
27% and 22% for entire group. There were no significant
differences between LCAF and LCAF + CT arms in
5-year (28% vs 40%), 8-year (21% vs 29%) and 10-year
(19% vs 23%) (Figure 1, p = 0.653).
From a univariate analysis, clinical stage and tumor
length at the long axis were demonstrated significant
prognostic factors for OS (Table 2). Overall survival on
attained age is illustrated in Figure 2-A.
Pattern of failures
Locoreginal failure
Locoregional failures were documented in 46 patients, of
whom 37 patients had recurrence in the esophagus, 6
patients in mediastinal nodes and both esophagus and
mediastinal nodes in 3 patients. Among locoregional re-
currence patients, 12 were diagnosed by biopsy and the
rest by CT and/or PET or endoscopy, but no biopsy was
performed either because of the patient’s refusal or due
to an esophageal lumen that was totally obstructed, thus
precluding biopsy.
Of the 46 locoregional failures, 42 were in-field
recurrences, which included 38 in in-boost dose region;
1, out-boost dose region; and 3, both in- and out-boostLCAF 57 28 17 15 12 10 2
LCAF+CT 54 32 19 18 14 11 3
No. at risk
Figure 1 Overall survival in patients treated with late course of
accelerated hyperfractionated irradiation (LCAF) alone (dashed
line) or LCAF with concurrent chemotherapy (LCAF + CT)
(solid line).
Table 2 Prognostic factors for overall survival in
esophageal squamous cell carcinoma treated by late
course of accelerated hyperfractionated irradiation
(LCAF) or late course of accelerated hyperfractionated
irradiation with concurrent chemotherapy (LCAF + CT)
Parameter P value
Age (≥ 70 yr vs. < 70 yr) 0.221
Stage (I vs. II + III) 0.047
KPS (≥ 90 vs. < 90) 0.633
Length (< 7 cm vs. ≥ 7 cm) 0.021
Treatment (LCAF vs. LCAF + CT) 0.653
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out-field mediastinal lymph nodes. The last patients
developed a second primary cardia carcinoma 22 months
after treatment.
Thirteen patients with locoregional recurrence received
salvage therapy including surgery (7), irradiation (4) and
chemoradiation (2). The remaining 33 patients received
no further therapy. Finally, four patients were salvagedBA
DC
Figure 2 Overall survival (A), locoregional recurrence rates (B), distan
age for entire group of 111 esophageal squamous cell carcinomas.and 42 died of locoregional recurrences or distant
metastases.
The locoregional recurrence rates are shown in
Figures 3 and 2-B and they were relatively constant
after three years. The locoregional recurrence occurred
more often in the first two to three years and then
increased steadily at a low rate for up to 13 years after
treatments. For all 111 patients, the 5-year, 8-year and
10-year locoregional recurrence rates were 30%, 36%
and 41% respectively. For LCAF, these rates were 35%,
40% and 44% and for LCAF + CT they were 25%, 32%
and 40% respectively (p= 0.558) (Figure 4-A).
Distant metastasis
Distant metastases developed in 32 patients, including
distant node disease (11), lungs (11), bone (3), brain (2),
liver (1), stomach (1) and multiple organs (3). Distant
metastasis rates are illustrated in Figures 3 and 2-C. The
majority of distant failures occurred three years after
therapy and hazard rate (HR) was constant after three
years. For the entire group, the 5-year, 8-year, and 10-t metastasis rates (C) and late toxicity incidences (D) on attained
Figure 3 Locoregional recurrence (solid line) and distant metastasis (dashed line) rates for entire group of 111 esophageal squamous
cell carcinomas. A: The probability was plotted on linear scale; B: The probability was plotted on logarithmic scale.
BA
C
Figure 4 Locoregional recurrence (A), distant metastasis (B) and late toxicity (C) in esophageal squamous cell carcinoma treated by
late course of accelerated hyperfractionation accelerated irradiation (LCAF) (dashed line) or LCAF concurrent chemotherapy (LCAF +
CT) (solid line).
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Table 3 Quality of life evaluation in 17 patients alive at
the last follow-up visit
QOL No. of patients (%)
KPS ≥ 90 15 (88%)
70-80 2 (12%)
Diet Regular 13 (76%)
Soft food 3 (18%)
Semi-fluid 1 (6%)
Cough No 13 (76%)
Grade 1 4 (24%)
Hemoptysis No 16 (94%)
Grade 1 1 (6%)
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spectively. There was no significant difference between
the two arms, namely 5-year, 8-year, and 10-year distant
metastasis rates of 30%, 32% and 33% for LCAF, respect-
ively, and 23%, 25% and 25% for LCAF + CT, respect-
ively (p= 0.264) (Figure 4-B).
Late toxicity
Grade 3 or higher late toxicities occurred in 32 patients
(29%), including pulmonary fibrosis in 21 patients (19%),
esophageal stenosis in 10 patients (9%) and pericarditis in
1 patient (1%). Five out of these 32 patients died of pul-
monary or heart failures due to the severe pulmonary fi-
brosis. The cumulative late toxicity incidences at 5-years,
8-years and 10-years were 26%, 29% and 29%, respectively.
There was no significant difference between the two arms,
namely 30%, 33% and 33% for LCAF and 21%, 26% and
26% for LCAF + CT (p=0.161) (Figure 4-C).
The incidence of late toxicities of Grade 3 or greater
on attained age is also displayed in Figure 2-D. At the
attained age of 50-year, cumulative probability of late
toxicities was less than 10% and it rose to about 30% at
the attained age of 70-years. However, at 80-years it rose
to 70%.
Five patients (three patients in LCAF and two patients
in LCAF + CT) succumbed to intercurrent diseases.
Two of the deaths resulted from massive hemoptysis at
eight months and 14 months after treatment. One pa-
tient had a lethal pulmonary infection, which led to re-
spiratory failure six months after therapy. One patient
died of pulmonary infarction 31 months after treatment.
The last patient who did not have any history of cardio-
vascular diseases died of a heart attack at the age of 60,
six years after treatment.
One patient developed a second primary cancer, leio-
myosarcoma, four years after therapy, located in the irra-
diated segment of esophagus. This patient received surgery
and was doing well up until the last follow-up visit.
QOL
QOL was not evaluated periodically or well documented
due to over 10 years of follow-up, which made the data
disintegrated. Therefore, here, we presented QOL data
on 17 living patients at the last follow-up with median
follow-up time of 138 months (Table 3). Fifteen of
patients (88%) lived with good KPS (≥ 90). Thirteen
patients (76%) could eat regular food. Cough and
hemoptysis occurred at Grade 1 in 24% and 6% of the
patients, respectively.
Discussion
We reported that the long-term outcome of our clinical
trial on esophageal SCC treated by LCAF alone or LCAF
with concurrent chemotherapy after a 10-year follow-upperiod. For esophageal carcinoma, the concurrent che-
moradiation has been recognized as the standard of care.
However, the long-term outcome for failure patterns and
very late treatment related toxicity has never been
reported. Therefore, our study could be of significant
interest to oncologists who are involved in the treatment
of esophageal cancers.
Survival
Five-year, 8-year and 10-year overall survival rates in our
study were 34%, 27% and 22% respectively, which were
comparable to the rates in concurrent chemoradiation in
RTOG 8501 [7]. However, no significant difference was
noticed between patients in LCAF alone and LCAF +
CT, despite a trend of higher survival in chemoradiation
around five years after treatment.
Failure patterns
Findings observed in the failure patterns were interest-
ing. It was obvious that locoregional failures continu-
ously occurred up to ten years after treatment, although
more often in the first three years. However, distant me-
tastasis developed mostly in the first three years, and
thereafter, increased slowly up to ten years. This result
suggested that in the first three years, both locoregional
and distant failures were major problems, but locoregio-
nal failures for long-term survivors should not be disre-
garded. For long-term survivors of esophageal SCC, the
biological behaviors of the tumors were probably less
malignant than that of the others, and thus less distant
metastases occurred.
Toxicity
We have already reported the acute toxicity in our previ-
ous publication, including severe (≥ Grade 3) acute radi-
ation induced lung disease in 24 patients (22%) and
severe (≥ Grade 3) esophagitis in 5 patients (5%) [3].
Late complications of Grade ≥ 3 were recorded in 32
patients (29%), mainly in the first three years after
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ten years. The predominant late complications were
pulmonary fibrosis and esophageal stenosis, which fi-
nally resulted in 16% (5/32) mortality. There were 29%
of patients with late complications in our study, which
was comparable to those reported by previous studies
(28%-46%) [7-11]; despite the higher tumor dose in this
study than those in RTOG 8501. It could be attributed
to the lack of prophylactic irradiation to mediastinal,
supraclavicular and celiac nodes and a reduced irradi-
ation field after 41.4 Gy. Furthermore, the use of hyper-
fractionation further reduced the irradiation-induced
toxicity.
The interesting finding from this study is the cumula-
tive incidences of late complications (Figure 2-D). From
age 40 to 50 years, the late toxicity incidence appeared
to be relatively low (< 5%). From 50 years to 70 years, it
accumulated at a more rapid rate to approximately 30%.
After 70 years, it rose remarkably to over 70%. This
showed that the prevalence of late toxicities was a mani-
festation for elderly patients. This finding is consistent
with recent publications on pelvic cancers after com-
bined therapy. The results from the Medical Research
Council RT01 Trial showed that age was associated with
late rectal bleeding and late proctitis in prostate cancer
[12]. In a Swedish study of 1147 patients with rectal can-
cer, it was also evident that older patients (aged 75 years
and above) were at greater risk of late gastrointestinal
bleeding (RR= 3.81) [13]. Therefore, the late toxicity
induced by treatments was predominantly a problem
that occurred in the elderly population. Therefore, con-
sidering that late toxicities of Grade 3 or greater were
more likely to occur in elderly patients with esophageal
SCC, we proposed that chemoradiation should be cau-
tiously delivered to elderly patients due to their higher
risk for late toxicity.
Five patients died of intercurrent diseases with neither
≥ Grade 3 late complications nor disease recurrences;
thus, we believe that their deaths could be partly attribu-
ted to irradiation or chemotherapy. One patient died of
pulmonary infection, which could have resulted from
jeopardized immune response after treatment. An inva-
sion of great vessels could be one of the reasons two
patients died of massive hemoptysis. The other two
patients who died of pulmonary infarction and heart at-
tack likely had injuries of blood vessels by irradiation as
contributing factor to their death. Another possibility
might be that radiation-induced injury of vessels wor-
sened their pre-existed vascular diseases. The exact ir-
radiation doses to heart and blood vessels were,
however, unknown because of the lack of 3-dimensional
dose distributions. A second primary tumor of esopha-
geal leiomyosarcoma could also be related to chemora-
diation. Therefore, for long-term survivors, we shouldalso be aware of the risk of treatment-induced secondary
primary malignancies.
QOL
For 17 living patients, after a median follow-up time of
138 months, their QOL was quite good. A majority of
the patients lived with good performance status and
could eat regular food with no severe treatment-related
sequences. In the current study, we used a two-
dimensional irradiation technique, whereas the late com-
plications were acceptable. If modern irradiation techni-
ques of three-dimensional conformal radiation therapy
or intensity modulated radiation therapy were used, the
late toxicity could be further reduced.
In spite of our effort, the outcome was still not satis-
factory for esophageal SCC patients. A prospective clin-
ical trial on concurrent use of chemoradiation and
nimotuzumab, a monoclonal antibody against epidermal
growth factor receptor, is underway in our center in an
effort to further improve local control and survival for
esophageal SCC patients [14].
In conclusion, the local control and survival of LCAF
irradiation with or without concurrent chemotherapy
was good after a 10-year follow-up for esophageal SCC.
The locoregional failure occurred gradually up to
10 years after treatment, as did distant metastasis, al-
though with a higher rate in the first three years. The
late complications were acceptable and patients’ QOL
was good. However, late treatment toxicities were more
likely to occur in elderly patients. Therefore, chemora-
diation should be cautiously delivered to the elderly
patients due to their higher risk for late toxicity.
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